131I Tositumomab

BioDrugs

Volumn 14, Issue 3, 2000, Pages 195-202

  Culy, C R ^a   Lamb, H M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIBODY; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; IMMUNOGLOBULIN ANTIBODY; IODINE 131; MONOCLONAL ANTIBODY I 131; RADIOPHARMACEUTICAL AGENT; TOSITUMOMAB I 131; UNCLASSIFIED DRUG;

ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TOXICITY; CLINICAL TRIAL; DOSIMETRY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FLU LIKE SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MEAN RESIDENCE TIME; NEUTROPENIA; NONHODGKIN LYMPHOMA; OCCUPATIONAL HAZARD; PRIORITY JOURNAL; PRURITUS; RADIATION EXPOSURE; REVIEW; THROMBOCYTOPENIA; VOMITING;

EID: 0033786051     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200014030-00005     Document Type: Review

References (29)

1. Non-Hodgkin's lymphoma: A review of immunotherapeutic approaches to treatment
2. Clinical practice guidelines: Non-Hodgkin's lymphomas
3. Quality of life in patients with low-grade non-Hodgkin's lymphoma
4. Current approaches to therapy for indolent non-Hodgkin's lymphoma
5. A revolution in the treatment of non-Hodgkin's lymphoma
6. Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates
7. Monoclonal antibody therapy of patients with non-Hodgkin's lymphomas
8. Iodine-131-Anti-B1 radioimmunotherapy for B-cell lymphoma
9. Radioimmunotherapy: Recent results and future directions
10. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
11. Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation
12. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations
13. Pharmacokinetics of I-131 anti-B1 (anti-CD20) antibody radiolabelled on-site vs. centrally
14. Effect of patient/disease characteristics on I-131 anti-B1 (anti-CD20) antibody pharmacokinetics
15. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy
16. Radiolabelled-antibody therapy of B-cell lymphoma with autologous bone marrow support
17. A multicenter phase II study of iodine-131 anti-B1 antibody (Bexxar) in patients with chemotherapy-relapsed/refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma
18. Successful re-treatment of non-Hodgkin's lymphoma with iodine-131 anti-B1 antibody
19. Multicenter, phase III study of iodine-131 tositumomab (anti-B1-antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma
20. Randomized controlled study of iodine-131 antibody vs. unlabelled antibody in patients with chemotherapy refractory low-grade non-Hodgkin's lymphoma
21. A phase II trial of iodine-131-labelled anti-CD20 (B1) antibody therapy with bone marrow transplantation for relapsed non-Hodgkin's lymphomas
22. A phase I/II trial of high dose iodine-131-anti-B1 (anti-cd20) monoclonal antibody, etoposide, cyclophosphamide, and autologous stem cell transplantation for patients with relapsed B cell lymphomas
23. Front-line treatment of advanced B-cell low-grade lymphoma (LGL) with radiolabelled anti-B1 antibody:Initial experience
24. Fludarabine monophosphate followed by iodine I 131 tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma (NHL)
25. Radioimmunotherapy of B-cell lymphoma with I-131 anti-B1 (anti-CD20) antibody
26. Independent review of response to iodine-131 anti-B1 antibody in low-grade or transformed low-grade non-Hodgkin's lymphoma
27. Iodine-131 anti-B1 antibody for non-Hodgkin's lymphoma: Overall clinical trial experience
28. A new approach to patient release following iodine-131 anti-B1 antibody therapy
29. Annual Report 1998: Letter from Michael F Bigham (President and Chief Executive Officer.)